FDA has set an Aug. 18, 2025, target date for Chimerix’s dordaviprone NDA for recurrent H3 K27M-mutant diffuse glioma. Feel unsure about the market’s next move? Copy trade alerts from Matt ...

Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ( ...

One of its products includes the ONC201, which is a program in a Phase 3 clinical trial for patients with H3 K27M-mutant diffuse glioma, as well as in a Phase 2 clinical trial for the treatment of ...

Chimerix, a biopharmaceutical company, announced that the New Drug Application (NDA) for its drug Dordaviprone, aimed at treating recurrent H3 K27M-mutant diffuse glioma, is under review with a ...

The Company's most advanced clinical-stage development program, dordaviprone, is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to ...

New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 ...